Noctrix Health

About Noctrix Health

Noctrix Health, Inc. provides a focused non-pharmacologic therapy for a specific subset of patients with chronic neurological conditions. The company operates within the medical device and therapeutic wearables market, targeting individuals with moderate-to-severe, medication-refractory Restless Legs Syndrome (RLS). Its business model centers on a prescription-based approach, making its device available to patients through healthcare providers.

The company's origins trace back to the Stanford Biodesign Innovation Program, where the significant unmet need for better RLS treatments was identified. Founded in 2016 and incorporated in 2018 by Shriram Raghunathan and Jonathan Charlesworth, the firm was built on a foundation of combined expertise. Raghunathan, President and CEO, has a background in engineering, neuromodulation, and medical device design, while Charlesworth contributes his experience as a neuroscientist. Their collaboration aims to establish wearable therapeutics as a standard treatment option for RLS patients.

Noctrix Health's primary offering is the NTX100 Tonic Motor Activation (TOMAC) System, marketed as Nidra™. This prescription device consists of a pair of bands worn on the lower legs during the night. The system works by delivering electrical impulses to the peroneal nerves, which generates a sustained, low-level muscle activation. This neurostimulation is designed to be compatible with sleep and effectively suppresses the uncomfortable sensations characteristic of RLS. The key benefit is providing relief and improving sleep quality for patients who have not found success with or cannot tolerate pharmaceutical treatments. A notable milestone was achieved in April 2023, when the U.S. Food and Drug Administration (FDA) granted De Novo marketing authorization for the NTX100 system, following a 'Breakthrough Device Designation' in 2020. This authorization was supported by a successful multi-center, randomized controlled trial involving 133 patients, which demonstrated the therapy's efficacy and safety.